Glioblastoma Multiforme Treatment (GBM) Market Will Increase Strongly Through 2022
Obtain Report Details @http://www.transparencymarketresearch.com/pipeline-review-of-glioblastoma-treatment-market.html
Although, the rising mortality rate of GBM has made it one of the lethal type of cancers; the pipeline of GBM is well equipped with various types of novel therapies including immunotherapy, biologics, small molecules and other drugs. The pipeline of GBM is currently rich in number of various therapeutic drugs and devices that are expected to receive FDA approvals for conducting the clinical trials. The FDA approved drugs currently present in market are temozolomide (Temodar, Temodal and Temcad), bevacizumab (Avastin) and carmustine wafers (BiCNU). The geographical segmentation of GBM market comprises North America, Europe, Asia Pacific and Rest of the World. Bevacizumab (Avastin) is the latest addition to this artillery, while temozolomide was leading the GBM market in 2013 due to it’s effectiveness when combined with surgery. Bevacizumab is the first monoclonal antibody drug approved for GBM treatment which is more efficient than temozolomide and is expected to surpass its revenue by 2016. Temozolomide market was drastically affected in 2013 as it has lost the market exclusivity in 2012 and generics manufactured by Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd. entered the market. Geographically, in 2013 North America was observed as the most leading GBM market due to increasing support from government and non-government organizations to raise public awareness by and advanced healthcare infrastructure to boost the pipeline research in this market. Asia Pacific is the fastest growing market, rising awareness against GBM is boosting the diagnostic rate in this region and developing healthcare infrastructure is also assisting the market growth.
The pipeline analysis of GBM treatment include biologics, small molecules, devices, surgeries, and immunotherapy. In the current scenario, the pipeline review of glioblastoma seems to be strong as more than 50 molecules are in phase I and phase II clinical trials. The most promising drugs in phase III trials are Rindopepimut or CDX-110 (Celldex Therapeutics) and DCVax-L (Northwest Biotherapeutics). These molecules have performed well in phase II of the clinical trials in terms of exceeding the overall survival rate.
Fill The Form To Gain Deeper Insights On This Market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4807
The key players involved in the GBM market are Abbvie, Inc., Celldex Therapeutics, Inc., Exellixis, Inc., Brostol-Myers Squibb Co. and F. Hoffman La Roche. In 2013, F. Hoffman La Roche was observed to be the most promising and efficient source of GBM treatment due to its novel drug delivery system known as “brain shuttle.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Transparency Market Research
90 State Street,
NY - 12207
USA - Canada Toll Free 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glioblastoma Multiforme Treatment (GBM) Market Will Increase Strongly Through 2022 here
News-ID: 541506 • Views: 396
More Releases from Transparency Market Research
Marketing Automation Market Value Projected To Expand By 2020-2030
Global Marketing Automation Market: Introduction Marketing automation is a technology that manages marketing processes and multifunctional campaigns across multiple channels, automatically. It enables customer targeting through automated messages across email, web, social, and text mediums. Messages are sent automatically, according to sets of instructions called workflows. Marketing and sales departments majorly use marketing automation to automate online marketing campaigns and sales activities to both increase revenue and maximize efficiency. Get report details: https://www.transparencymarketresearch.com/marketing-automation-market.html Global Marketing
Workflow Automation Market To Observe Strong Development by 2019 – 2027
Global Workflow Automation Market: Overview The global workflow automation market is growing at a stellar pace in recent times. The business sector has undergone grassroot-level changes, and has embraced new technologies. Processes that can expedite the growth of businesses are readily adopted across industrial frameworks. There is a stellar need for improved workflows and functionalities across businesses, and industry leaders are earnest about accomplishing this requirement. The past decade has
VR Gaming Accessories Market Poised to Expand at a Robust Pace Over 2021-2031
VR Gaming Accessories Market – Introduction VR gaming or virtual reality gaming refers to computer games that use virtual reality to give participants the experience of a game environment through a variety of VR gaming accessories such as sensor equipped gloves, VR headsets, and hand controllers. The growing demand for VR gaming, especially among the youth, offers great opportunities for companies in the global VR gaming accessories market. Get report details: https://www.transparencymarketresearch.com/vr-gaming-accessories-market.html Key
Night Creams Market Progresses for Huge Profits During 2017 – 2026
Exposure of the skin to excessive heat, pollution, dust can cause accumulation of toxic substances that can lead to irritation and other skin problems such as acne, pimples, and dark spots. To maintain their skin health during the day and night time, individuals are spending on a range of personal care products and face washes. Capitalizing on the growing skin requirements of the customers, leading companies are concentrating on offering
More Releases for GBM
Understanding Impact of COVID-19 on Glioblastoma Multiforme (GBM) Market
Glioblastoma Multiforme (GBM), also known as glioblastoma, is a form of brain cancer. It is a rapidly-growing glioma that develops from star-shaped glial cells, such as oligodendrocytes and astrocytes that support the nerve cells in the brain. GBM is also called as grade IV astrocytoma and is among the most invasive forms of glial tumors. It is a fast-growing and aggressive form of tumor in the central nervous system (CNS)
2019 - 2025 Glioblastoma Multiforme Treatment Market | GBM Market
Global Glioblastoma Multiforme Treatment Market, Its Market Trends And Analysis Glioblastoma multiforme is the high-grade glioma and potent malignant brain tumor that affects glial cells. Glioblastoma multiforme contains the complexly differentiated neoplastic astrocytes which are the subtype of central nervous system. Glioblastoma multiforme is different from the anaplastic astrocytoma due to the presence of hyperplastic blood vessels and necrotic tissue. Request Sample Report: https://precisionbusinessinsights.com/request-sample?product_id=16248 The global glioblastoma multiforme treatment market is
Glioblastoma Multiforme Treatment (GBM) Market is exhibiting a positive CAGR of …
Keen players in the global glioblastoma multiforme (GBM) treatment market are striving to maintain their foothold via novel product offerings. These players are focusing hard on the development of newer biological drugs with fewer side effects, which are usually associated with the consumption of immunosuppressants and chemotherapeutic agents. Collaborations with diagnostic laboratories in order to raise awareness regarding treatment options for glioblastoma multiforme is another key growth strategy adopted by market
Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2016
Summary: ReportsWeb.com published “Glioblastoma Multiforme (GBM)” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Original Content: Publisher's clinical trial report, "Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2016" provides an overview of Glioblastoma Multiforme (GBM) clinical trials scenario. This report provides top line data relating to the clinical trials
Glioblastoma Multiforme Treatment (GBM) Industry Analysis by Segments
Glioblastoma multiforme (GBM) is a high-grade gliomas and the most malignant astrocytic tumor, composed of complexly differentiated neoplastic astrocytes, a subtype of central nervous system (CNS). Glioblastoma is clinically classified as grade IV astrocytoma and differs from anaplastic astrocytoma (grade III) due to the presence of necrotic tissue and hyperplastic blood vessels. The diagnosis of GBM is carried out with imaging modules such as computed tomography (CT), magnetic resonance imaging
Global Recurrent Glioblastoma Multiforme (GBM) Treatment Market, 2016 - 2022
Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans that involves glial cells. GBM is present in two variants namely, giant cell glioblastoma and gliosarcoma. Gliomas are tumors arising from glial cells and may occur in the spinal cord or the brain, the latter being more common. Gliomas are the most common type of brain tumor and can be either supratentorial or infratentorial. Seizure,